- cafead Apr 25, 2019 at 12:22: PM
via Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two.
The company, which was testing its immuno-oncology star alongside Yervoy in previously treated patients whose disease had recurred or spread, said Thursday that the pair had failed to outdo Opdivo on its own.
article source
The company, which was testing its immuno-oncology star alongside Yervoy in previously treated patients whose disease had recurred or spread, said Thursday that the pair had failed to outdo Opdivo on its own.
article source